Trevi Therapeutics Inc. has landed a tranched $25 million series B financing to support two pivotal trials of Nalbuphine extended release (ER), its oral opioid in development for the treatment of two forms of severe itching. TPG Biotech, which has funded the company since its founding, was the sole investor.